About: Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope
Creator	Montefiori, David Ansari, Rais Park, Hanna Penn-Nicholson, Adam Han, Dong Cho, Michael Kim, Soon
Source	Elsevier; Medline; PMC
abstract	Human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 is targeted by broadly-reactive neutralizing antibodies 2F5 and 4E10, making it an attractive target for vaccine development. To better assess immunogenic properties of gp41, we generated five soluble glutathione S-transferase fusion proteins encompassing C-terminal 30, 64, 100, 142, or 172 (full-length) amino acids of gp41 ectodomain from M group consensus envelope sequence. Antibody responses in HIV-1-infected patients were evaluated using these proteins and overlapping peptides. We found (i) antibody responses against different regions of gp41 varied tremendously among individual patients, (ii) patients with stronger antibody responses against membrane-proximal external region exhibit broader and more potent neutralizing activity, and (iii) several patients mounted antibodies against epitopes that are near, or overlap with, those targeted by 2F5 or 4E10. These soluble gp41 fusion proteins could be an important source of antigens for future vaccine development efforts.
has issue date	2008-03-01(xsd:dateTime)
bibo:doi	10.1016/j.virol.2007.11.009
bibo:pmid	18068750
has license	green-oa
sha1sum (hex)	60a3936ab4ac68d18c6ae1da313774b37d84e087
schema:url	https://doi.org/10.1016/j.virol.2007.11.009
resource representing a document's title	Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope
has PubMed Central identifier	PMC2293309
has PubMed identifier	18068750
schema:publication	Virology
resource representing a document's body	covid:60a3936ab4ac68d18c6ae1da313774b37d84e087#body_text
is schema:about of	named entity 'USING' named entity 'PROTEINS' named entity 'ENVELOPE' named entity 'EVALUATED' named entity 'SOLUBLE' named entity 'ANTIBODY' named entity 'DERIVED' named entity 'BETTER' named entity 'C-TERMINAL' named entity 'INDIVIDUAL' named entity 'SEQUENCE' named entity 'REACTIVE' named entity 'SOURCE' named entity 'FOUND' named entity '172' named entity 'OVERLAP WITH' named entity 'EXHIBIT' named entity 'PROPERTIES' named entity 'EXTERNAL' named entity 'RESPONSES' named entity 'GROUP CONSENSUS' named entity 'ANTIBODY' named entity 'GLUTATHIONE S-TRANSFERASE' named entity 'ANTIGENS' named entity 'ATTRACTIVE' named entity 'ASSESS' named entity 'REGIONS' named entity 'FUSION' named entity '100%' named entity 'PATIENTS' named entity 'HIV-1' named entity 'GP41' named entity 'INFECTED' named entity 'ASSESSMENT' named entity 'REGION' named entity 'TRANSMEMBRANE GLYCOPROTEIN' named entity 'EPITOPES' named entity 'GROUP CONSENSUS' named entity 'TARGETED' named entity 'NEAR' named entity 'FUSION' named entity 'PEPTIDES' named entity '30%' named entity 'ECTODOMAIN' named entity 'HIV-1' named entity 'AMINO ACIDS' named entity 'GP41' named entity 'FUTURE' named entity '28I' named entity 'PROTEINS' named entity 'PEPTIDES' named entity 'HUMAN IMMUNODEFICIENCY VIRUS TYPE 1' named entity 'THESE' named entity 'ACTIVITY' named entity 'USING' named entity 'RESPONSES' named entity 'IMPORTANT' named entity 'IMMUNOGENIC' named entity 'MEMBRANE' named entity 'SOLUBLE' named entity 'GENERATED' named entity 'PATIENTS' named entity 'INFECTED' named entity 'DIFFERENT' named entity 'TARGET' named entity 'MOUNTED' named entity 'PROXIMAL' named entity 'ENVELOPE' named entity 'NEUTRALIZING ANTIBODIES' named entity 'ANTIBODIES' named entity 'OVERLAPPING' named entity 'COULD BE' named entity 'VACCINE DEVELOPMENT' covid:arg/60a3936ab4ac68d18c6ae1da313774b37d84e087 named entity 'gp41'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software